Highlights IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
41.17 ^USD	+1.30%		-2.39%	+15.71%

08/05	Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating	MT
07/05	IDEAYA Biosciences Shares Fall After Q1 Loss	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IDEAYA Biosciences Shares Fall After Q1 Loss	07/05	MT
IDEAYA Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy	22/04	MT
IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	22/04	CI
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer	12/03	CI
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines	20/02	MT
Earnings Flash (IDYA) IDEAYA BIOSCIENCES Posts Q4 Revenue $3.9M	20/02	MT
IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/02	CI
IDEAYA Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/02	CI
IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer	04/12	MT
Ideaya Biosciences, Inc. Announces Clinical Study Collaboration with Gilead Sciences, Inc. to Evaluate Trodelvy and Ide397 Combination in Mtap-Deletion Bladder Cancer	04/12	CI
IDEAYA Biosciences, Inc. Enters into an Office Lease Agreement with AAT TORREY 13-14, LLC to Expand Its Current Office Space in San Diego	17/11	CI
IDEAYA Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Earnings Flash (IDYA) IDEAYA BIOSCIENCES Posts Q3 Revenue $8M	07/11	MT
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline	23/23/23	CI
Ideaya Biosciences Says US FDA Grants Fast Track Designation for IDE161 for Ovarian Cancer	26/23/26	MT
Ideaya Biosciences, Inc. Receives Fast Track Designation for Potential First-In-Class Parg Inhibitor, Ide161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients Having Tumors with Brca1/2 Mutations	26/23/26	CI
IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Adjuvant Uveal Melanoma	16/23/16	CI
IDEAYA Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Earnings Flash (IDYA) IDEAYA BIOSCIENCES Reports Q2 Revenue $3.5M	10/23/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Highlights

Filters